Significance of Hypouricaemia in the Development of Neurodegenerative Diseases

Ames, B. N., Cathcart, R., Schwiers, E., Hochstein P. (1981). Uric acid provides an antioxidant defense in humans against oxidant- and radical-caused aging and cancer: A hypothesis. Proc. Natl. Acad. Sci.,78 (11), 6858–6862.10.1073/pnas.78.11.68583491516947260Search in Google Scholar

Bardin, T., Keenan, R.T., Khanna, P. P., Kopicko, J., Fung, M., Bhakta, N., Adler, S., Storgard, C., Baumgartner, S., So, A. (2017). Lesinurad in combination with allopurinol: A randomised, double-blind, placebo-controlled study in patients with gout with inadequate response to standard of care (the multinational CLEAR 2 study). Ann. Rheum. Dis., 76 (5), 811–820.10.1136/annrheumdis-2016-209213553033627821644Search in Google Scholar

Becker, M. A., Schumacher, R. H., Wortmann, R. L., MacDonald, P. A., Eustace, D., Palo, W. A., Streit, J., Joseph-Ridge, N. (2005). Febuxostat compared with allopurinol in patients with hyperuricemia and gout. New Engl. J. Med.,353 (23), 2450–2461.10.1056/NEJMoa05037316339094Search in Google Scholar

Becker, B. D., Coremans, C., Chaumont, M., Delporte, C., Antwerpen, P. V., Franck, T., Rousseau, A., Boudjeltia, K. Z., Cullu, P., Borne, P. V. D. (2019). Severe hypouricemia impairs endothelium-dependent vasodilatation and reduces blood pressure in healthy young men: A randomized, placebo-controlled, and crossover study. J. Amer. Heart Assoc.,8 (23), e013130.10.1161/JAHA.119.013130691296731752638Search in Google Scholar

Bellomo, G., Selvi, A. (2018). Uric acid: The lower the better? Contrib. Nephrol., 192, 69–76.Search in Google Scholar

Braga, T. T., Forni, M. F., Correa-Costa, M., Ramos, R. N., Barbuto, J. A., Branco, P., Castoldi A., Hiyane M. I., Davanso M. R., Latz E., Franklin B. S., Kowaltowksi A., Camara, N. O. S. (2017). Soluble uric acid activates the NLRP3 inflammasome. Sci. Rep.,7 (1), 39884.Search in Google Scholar

Bowman, G. L., Shannon, J., Frei, B., Kaye, J. A., Quinn, J. F. (2010). Uric acid as a CNS antioxidant. J. Alzheimers Dis.,19 (4), 1331–1336.10.3233/JAD-2010-1330285918520061611Search in Google Scholar

Chen, X., Guo, X., Huang, R., Chen, Y., Zheng, Z., Shang, H. (2014). Serum uric acid levels in patients with Alzheimer’s Disease: A meta-analysis. PLOS ONE,9 (4), e94084.10.1371/journal.pone.0094084397975624714617Search in Google Scholar

Cho, S. K., Chang, Y., Kim, I., Ryu, S. (2018). U-Shaped association between serum uric acid level and risk of mortality. Arthritis Rheumatol.,70 (7), 1122–1132.10.1002/art.4047229694719Search in Google Scholar

Dalbeth, N., Jones, G., Terkeltaub, R., Khanna, D., Kopicko, J., Bhakta, N., Adler, S., Fung, M., Storgard, C., Baumgartner, S., Perez-Ruiz, F. (2017). Lesinurad, a selective uric acid reabsorption inhibitor, in combination with Febuxostat in patients with tophaceous gout: Findings of a Phase III clinical trial. Arthritis Rheumatol.,69 (9), 1903–1913.10.1002/art.40159560120028597604Search in Google Scholar

Esparza Martin, N., Garcia Nieto, V. (2011). Hypouricemia and tubular transport of uric acid. Revista Nefrologia, 31, 44–50.Search in Google Scholar

Fang, P., Li, X., Luo, J.J., Wang, H., Yang, X. (2013). A double-edged sword: Uric acid and neurological disorders. Brain Disord. Ther.,2 (2), 109.Search in Google Scholar

Fujinaga, S., Ito, A., Nakagawa, M., Watanabe, T., Ohtomo, Y., Shimizu, T. (2013). Posterior reversible encephalopathy syndrome with exercise-induced acute kidney injury in renal hypouricemia type 1. Eur. J. Pediatrics, 172 (11), 1557–1560.10.1007/s00431-013-1986-723525542Search in Google Scholar

Graf, S. W., Whittle, S. L., Wechalekar, M. D., Moi, J. H. Y., Barrett, C., Hill, C. L., Littlejohn, G., Lynch, N., Major, G., Taylor, A. L., Buchbinder, R., Zochling, J. (2015). Australian and New Zealand recommendations for the diagnosis and management of gout: Integrating systematic literature review and expert opinion in the 3e Initiative. Int. J. Rheum. Dis.,18 (3), 341–351.10.1111/1756-185X.1255725884565Search in Google Scholar

Hui, M., Carr, A., Cameron, S., Davenport, D., Doherty, M., Forrester, H.., Jenkins, W., Jordan, K. M., Mallen, C. D., McDonald, T. M., Nuki, G., Pywell, A., Zhang, W., Roddy, E. (2017). The British Society for Rheumatology Guideline for the Management of Gout. Rheumatology, 56 (7), e1–e20.Search in Google Scholar

Kanbay, M., Segal, M., Afsar, B., Kang, D.-H., Rodriguez-Iturbe, B., Johnson, R. J. (2013). The role of uric acid in the pathogenesis of human cardiovascular disease. Heart, 99 (11), 759–766.10.1136/heartjnl-2012-302535Search in Google Scholar

Kiltz, U., Alten, R., Fleck, M., Krüger, K., Manger, B., Müller-Ladner, U., Nuesslein, H., Reuss-Borst, M., Schwarting, A., Schulze-Koops, H., Tausche, A., Braun, J., (2017). Evidenzbasierte Empfehlung zur Diagnostik und Therapie der Gichtarthritis im fachärztlichen Sektor. Zeitschrift für Rheumatologie, 76 (2), 118–124 (in German).10.1007/s00393-016-0249-1Search in Google Scholar

Kocahan, S., Doğan, Z. (2017). Mechanisms of Alzheimer’s Disease pathogenesis and prevention: The brain, neural pathology, N-methyl-D-aspartate receptors, Tau protein and other risk factors. Clin. Psycho-pharmacol. Neurosci.,15 (1), 1–8.10.9758/cpn.2017.15.1.1Search in Google Scholar

Kuwabara, M. (2016). Hyperuricemia, cardiovascular disease, and hypertension. Pulse, 3 (3–4), 242–252.10.1159/000443769Search in Google Scholar

Longo, F. M., Massa, S. M. (2004). Neuroprotective strategies in Alzheimer’s disease. NeuroRx, 1 (1), 117–127.10.1602/neurorx.1.1.117Search in Google Scholar

Maiuolo, J., Oppedisano, F., Gratteri, S., Muscoli, C., Mollace, V. (2016). Regulation of uric acid metabolism and excretion. Int. J. Cardiol.,213, 8–14.10.1016/j.ijcard.2015.08.109Search in Google Scholar

Mattson, M. P. (2003). Excitotoxic and excitoprotective mechanisms: Abundant targets for the prevention and treatment of neurodegenerative disorders. NeuroMolecular Med., 3, 65–94.10.1385/NMM:3:2:65Search in Google Scholar

Mount, D. B., Sterns, R. H., Forman, J. P. (2020). Hypouricemia: Causes and clinical significance. UptoDate. https://www.uptodate.com/contents/hypouricemia-causes-and-clinical-significance (accessed 15 March 2021).Search in Google Scholar

Nakayama, A., Matsuo, H., Ohtahara, A., Ogino, K., Hakoda, M., Hamada, T., Hosoyamada, M., Yamaguchi, S., Hisatome, I., Shinomiya, N. (2019). Clinical practice guideline for renal hypouricemia (1st edition). Human Cell, 32 (2), 83–87.10.1007/s13577-019-00239-3643729230783949Search in Google Scholar

Olivares, D., Deshpande, V. K., Shi, Y., Lahiri, D. K., Greig, N. H., Rogers, J. T., Huang, X. (2012). N-Methyl D-Aspartate (NMDA) receptor antagonists and memantine treatment for Alzheimer’s Disease, vascular dementia and Parkinson’s Disease. Curr. Alzheimer Res.,9 (6), 746–758.10.2174/156720512801322564500234921875407Search in Google Scholar

Paganoni, S., Schwarzschild, M. A. (2016). Urate as a marker of risk and progression of neurodegenerative disease. Neurotherapeutics, 14 (1), 148–153.Search in Google Scholar

Pello, S., Boland, T., Dechant, V., Patel, S., Liang, T., Mandel, S. (2009). Uric acid’s relationship with stroke and Parkinson’s Disease: A review. Pract. Neurol.https://practicalneurology.com/articles/2009-july-aug/PN0809_07-php (accessed 15 March 2021).Search in Google Scholar

Perez-Gomez, M. V., Bartsch, L.-A., Castillo-Rodriguez, E., Fernandez-Prado, R., Kanbay, M., Ortiz, A. (2019). Potential dangers of serum urate-lowering therapy. Amer. J. Med.,132 (4), 457–467.10.1016/j.amjmed.2018.12.01030611833Search in Google Scholar

Richette, P., Doherty, M., Pascual, E., Barskova, V., Becce, F., Castañeda-Sanabria, J., Coyfish, M., Guillo, S., Jansen, T. L., Janssens, H., et al. (2017). 2016 updated EULAR evidence-based recommendations for the management of gout. Ann. Rheum. Dis., 76 (1), 29–42.10.1136/annrheumdis-2016-20970727457514Search in Google Scholar

Saag, K. G., Fitz-Patrick, D., Kopicko, J., Fung, M., Bhakta, N., Adler, S., Storgard C., Baumgartner S., Becker, M. A. (2017). Lesinurad combined with allopurinol: A randomized, double-blind, placebo-controlled study in gout patients with an inadequate response to standard-of-care allopurinol (a US-based Study). Arthritis Rheumatol.,69 (1), 203–212.10.1002/art.3984027564409Search in Google Scholar

Sautner, J., Gruber, J., Herold, M., Zwerina, J., Leeb, B. F. (2013). Österreichische 3e-Empfehlungen zu Diagnose und Management von Gicht 2013. Wiener Klinische Wochenschrift,126 (3–4), 79–89 (in German).Search in Google Scholar

Sautin, Y. Y., Johnson, R. J. (2008). Uric acid: The oxidant-antioxidant paradox. Nucleosides Nucleotides Nucl. Acids,27 (6), 608–619.10.1080/15257770802138558289591518600514Search in Google Scholar

Settle, T. (2014). The role of uric acid as an antioxidant in selected neurodegenerative disease pathogenesis: A short review. Brain Disord. Ther.,03 (03). https://www.researchgate.net/publication/269980495_The_Role_of_Uric_Acid_as_an_Antioxidant_in_Selected_Neurodegenerative_Disease_Pathogenesis_A_Short_Review (accessed 15 March 2021).Search in Google Scholar

Singh, J. (2019). Gout and neurological disease. Is there a link? Annual American College of Rheumatology Convergence, 11 November 2020.Atlanta, GA, USA.Search in Google Scholar

Squadrito, G. L., Cueto, R., Splenser, A. E., Valavanidis, A., Zhang, H., Uppu, R. M., Pryor, W. A. (2000). Reaction of uric acid with peroxynitrite and implications for the mechanism of neuroprotection by uric acid. Arch. Biochem. Biophys., 376, 333–337.10.1006/abbi.2000.172110775420Search in Google Scholar

Son, C.-N., Kim, J.-M., Kim, S.-H., Cho, S.-K., Choi, C.-B., Sung, Y.-K., Kim T.-H., Bae S.-C., Yoo D.-H., Jun, J.-B. (2016). Prevalence and possible causes of hypouricemia at a tertiary care hospital. Korean J. Intern. Med.,31 (5), 971–976.10.3904/kjim.2015.125501628226956409Search in Google Scholar

Sundy, J. S., Baraf, H. S. B., Yood, R. A., Lawrwnce Edwards, N., Gutierrez-Urena, S. R., Treadwell, E. L., Vasquez-Mellado, J., White, W. B., Lipsky, P., Horowitz, Z., et al. (2011). Efficacy and tolerability of pegloticase for the treatment of chronic gout in patients refractory to conventional treatment: Two randomized controlled trials. JAMA,306 (7), 711–720.Search in Google Scholar

Tana, C., Ticinesi, A., Prati, B., Nouvenne, A., Meschi, T. (2018). Uric acid and cognitive function in older individuals. Nutrients, 10 (8), 975.10.3390/nu10080975611579430060474Search in Google Scholar

Tausche, A.-K., Alten, R., Dalbeth, N., Kopicko, J., Fung, M., Adler, S., Bhakta N., Baumgartner S., Saag, K. (2017). Lesinurad monotherapy in gout patients intolerant to a xanthine oxidase inhibitor: A 6 month phase 3 clinical trial and extension study. Rheumatology, 56 (12), 2170–2178.10.1093/rheumatology/kex35029029210Search in Google Scholar

Weinstein, J. R, Anderson, S. (2010). The aging kidney: Physiological changes. Advances Chron. Kidney Dis.,17 (4), 302–307.10.1053/j.ackd.2010.05.002290162220610357Search in Google Scholar

White, W. B., Saag, K. G., Becker, M. A., Borer, J. S., Gorelick, P. B., Whelton, A., Gunawardhana, L., CARES Investigators (2018). Cardiovas-cular safety of febuxostat or allopurinol in patients with gout. New Engl. J. Med.,378 (13), 1200–1210.10.1056/NEJMoa171089529527974Search in Google Scholar

Yu, K.-H., Chen, D.-Y., Chen, J.-H., Chen, S.-Y., Chen, S.-M., Cheng, T.-T., Hsieh, S.-C., Hsieh, T.-Y., Hsu, P.-F., Kuo, C.-F., et al. (2018). Management of gout and hyperuricemia: Multidisciplinary consensus in Taiwan. Int. J. Rheum. Dis.,21 (4), 772–787.10.1111/1756-185X.1326629363262Search in Google Scholar

Zhang, W., Iso, H., Murakami, Y., Miura, K., Nagai, M., Sugiyama, D., Ueshima H., Okamura, T. (2016). Serum uric acid and mortality form cardiovascular disease: EPOCH-JAPAN study. J. Atherosclerosis Thrombosis, 23 (6), 692–703.10.5551/jat.31591739928026887218Search in Google Scholar